EXEL - EXELIXIS, INC.
IEX Last Trade
33.885
-0.040 -0.118%
Share volume: 30,500
Last Updated: Fri 27 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$33.92
-0.04
-0.12%
Fundamental analysis
36%
Profitability
35%
Dept financing
23%
Liquidity
67%
Performance
33%
Performance
5 Days
1.64%
1 Month
-5.29%
3 Months
31.09%
6 Months
51.04%
1 Year
41.50%
2 Year
119.83%
Key data
Stock price
$33.88
DAY RANGE
$33.72 - $34.25
52 WEEK RANGE
$20.42 - $36.97
52 WEEK CHANGE
$41.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Michael M. Morrissey
Region: US
Website: exelixis.com
Employees: 1,220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: exelixis.com
Employees: 1,220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.
Recent news